Abstract
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI
| Original language | English |
|---|---|
| Pages (from-to) | 1005-1014 |
| Number of pages | 10 |
| Journal | Journal of Korean medical science |
| Volume | 28 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2013 Jul |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. / Jeong, Jae Heon; Cho, Byoung Chul; Shim, Hyo Sup; Kim, Hye Ryun; Lim, Sun Min; Kim, Se Kyu; Chung, Kyung Young; Bakhtiar Ul Islam, S. M.; Song, Jae Jin; Kim, Soo Youl; Kim, Joo Hang.
In: Journal of Korean medical science, Vol. 28, No. 7, 07.2013, p. 1005-1014.Research output: Contribution to journal › Article
TY - JOUR
T1 - Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor
AU - Jeong, Jae Heon
AU - Cho, Byoung Chul
AU - Shim, Hyo Sup
AU - Kim, Hye Ryun
AU - Lim, Sun Min
AU - Kim, Se Kyu
AU - Chung, Kyung Young
AU - Bakhtiar Ul Islam, S. M.
AU - Song, Jae Jin
AU - Kim, Soo Youl
AU - Kim, Joo Hang
PY - 2013/7
Y1 - 2013/7
N2 - Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI
AB - Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI
UR - http://www.scopus.com/inward/record.url?scp=84880717979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880717979&partnerID=8YFLogxK
U2 - 10.3346/jkms.2013.28.7.1005
DO - 10.3346/jkms.2013.28.7.1005
M3 - Article
C2 - 23853482
AN - SCOPUS:84880717979
VL - 28
SP - 1005
EP - 1014
JO - Journal of Korean Medical Science
JF - Journal of Korean Medical Science
SN - 1011-8934
IS - 7
ER -